Argenx's big bid to stay ahead
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
Ash 2022 – Argenx faces Vyvgart questions
As the group looks to expand into immune thrombocytopenia, there are several reasons to be cautious.
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Roivant rewrites the Spac script, again
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
The Spac story departs from the script
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
Cholesterol fears rock Immunovant
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
